



Blaze Bioscience to Present Tumor Paint Clinical Data at 20th Annual Society for Neuro-Oncology (SNO) Meeting

Tumor Paint BLZ-100 interim data from study in patients with glioma

SEATTLE, WA– November 9, 2015 – [Blaze Bioscience, Inc.](#), the Tumor Paint Company®, a biotechnology company focused on guided cancer therapy, announced today that interim clinical data from the company’s Phase 1 study of Tumor Paint BLZ-100 in adult patients with brain cancer will be presented at the 20th Annual Society for Neuro-Oncology (SNO) Scientific Meeting to be held November 19-22, 2015 in San Antonio, Texas.

The presentation, titled “Phase 1 dose escalation and expansion safety study of BLZ-100 for fluorescence guided resection of glioma in adults,” will be presented by Dr. Dennis Miller of Blaze Bioscience on behalf of the clinical research teams from Cedars-Sinai Medical Center, Los Angeles, CA and Newro Foundation, Brisbane, Australia.

“We are very pleased with the progress made in this study to date. Data collected in this study thus far suggests that BLZ-100 is well tolerated and tumor-specific fluorescence can be achieved *in vivo*,” said Heather Franklin, President and CEO of Blaze Bioscience. “This clinical program will inform our plans for late stage clinical studies for Tumor Paint BLZ-100, which are anticipated to begin in 2016.”

Details of the poster presentation are as follows:

Date: Friday, November 20, 2015

Time: 7:30-9:30 p.m. Central Time

Location: Henry B. Gonzalez Convention Center – Ballroom B

Abstract Number: ATNT-16

About BLZ-100

BLZ-100 is the first product candidate from Blaze’s Tumor Paint platform and consists of an Optide (optimized peptide) and a fluorescent dye, which emits light in the near-infrared range. Tumor Paint products are designed to provide real-time, high-resolution intraoperative visualization of cancer cells, potentially enabling more precise, complete resection of cancer throughout surgery. Preclinical utility of Tumor Paint technology has been demonstrated in a wide range of cancer types. BLZ-100 is an investigational agent currently in multiple Phase 1 proof-of-concept clinical studies to evaluate the safety and imaging characteristics of BLZ-100 in solid tumors, including brain, breast, lung, prostate, colorectal, sarcoma, and skin cancer. More details about on-going trials are available at www.blazebioscience.com or www.clinicaltrials.gov.

About Blaze Bioscience

Blaze Bioscience, Inc. is a privately held biotechnology company focused on guided cancer therapy. Blaze was founded in 2010 by Dr. Jim Olson, a pediatric neuro-oncologist at the Fred Hutchinson Cancer Research Center and Seattle Children’s Hospital, and Heather Franklin, a former member of the executive management team at ZymoGenetics. Blaze is working to develop Tumor Paint products and Optide-based therapeutics. Surgery is first-line therapy for most solid tumor cancers and Tumor Paint

products have the potential to improve cancer surgery by providing real-time, high-resolution visualization of cancer cells throughout surgery. The ability to see cancer cells in real time and high resolution throughout surgery should enable better detection and more complete and precise surgical removal of cancer—while sparing surrounding normal tissue. In addition to the Tumor Paint platform, Blaze is collaborating with the Fred Hutchinson Cancer Research Center to discover and develop products based on knottin peptides as part of the Optides platform. This program extends the expertise gained in developing the Tumor Paint platform to optimized knottin peptides for therapeutic and imaging applications. For additional information, please visit www.blazebioscience.com.

#

Contact

Media-

Lauren Nelson

Blaze Bioscience, Inc.

(206) 535-8144

lauren.nelson@blazebioscience.com

Investor Relations-

Susan Specht Oram

SOS Communications LLC

(360) 535-3035

spechtoram@gmail.com